Bausch Health Companies (TSE:BHC) Stock Falls 0.7% – Here’s What Happened

Bausch Health Companies Inc. (TSE:BHC – Get Free Report)’s share price fell 0.7% during mid-day trading on Friday. The stock traded as low as C$8.69 and last traded at C$9.03. Approximately 407,227 shares traded hands during trading, a decline of 24% from the average session volume of 537,914 shares. The stock had previously closed at C$9.09.

Analyst Ratings Changes

Separately, Jefferies Financial Group raised shares of Bausch Health Companies to a “hold” rating in a report on Wednesday, July 22nd. Three investment analysts have rated the stock with a Hold rating. According to data from MarketBeat, Bausch Health Companies has an average rating of “Hold”.

View Our Latest Stock Analysis on Bausch Health Companies

Bausch Health Companies Stock Performance

The company has a debt-to-equity ratio of -1,173.29, a current ratio of 1.44 and a quick ratio of 0.58. The company has a 50 day simple moving average of C$8.66 and a 200-day simple moving average of C$7.86. The stock has a market cap of C$3.38 billion, a P/E ratio of -3.07, a price-to-earnings-growth ratio of 0.21 and a beta of 0.82.

Bausch Health Companies (TSE:BHC – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The company reported C$1.79 earnings per share (EPS) for the quarter. The firm had revenue of C$4.05 billion during the quarter. Bausch Health Companies had a positive return on equity of 87.57% and a negative net margin of 12.02%. On average, equities analysts expect that Bausch Health Companies Inc. will post 5.55 earnings per share for the current fiscal year.

About Bausch Health Companies

(Get Free Report)

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

Read More

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.